H.C. Wainwright cuts XOMA stock rating on Ligand acquisition By Investing.com

H.C. Wainwright downgraded XOMA to Neutral from Buy after Ligand Pharmaceuticals announced a $739 million cash acquisition at $39.00 per share, implying a 14% premium to XOMA Royalty’s 30-day VWAP. XOMA also reported Q4 2025 EPS of $0.26 versus a forecast loss of $0.11 and revenue of $13.76 million versus $11.13 million expected, while the deal includes a contingent value right tied to 75% of certain litigation proceeds. The article is mixed overall: the downgrade is negative, but the earnings beat and takeover premium are supportive.

Analysis

This is less a company-specific downgrade story than a capital-allocation signal for the healthcare royalty complex: the buyer is effectively paying up for a de-risked stream of cash flows, which should compress the discount rate on comparable royalty aggregators. That matters for holders of smaller, litigation- or milestone-exposed names because the market may now value “portfolio quality” over headline growth, especially if financing markets stay selective.

The second-order winner is Ligand, but the market may underappreciate integration risk: royalty portfolios look clean on paper, yet the real value comes from post-close diligence on claim structures, counterparty concentration, and legal optionality. If Ligand successfully monetizes the pending litigation CVR, the deal becomes an accretive proof point for using balance sheet capacity to harvest asymmetric legal assets; if the litigation drags or underdelivers, the premium paid can look expensive within a few quarters.

The most interesting contrarian angle is that the target’s strong operating print may be exactly why the buyer acted now. If the underlying asset base is inflecting, waiting would raise the acquisition price and reduce deal certainty, so the current valuation could reflect a strategic ceiling rather than fair value. That creates a near-term spread opportunity: the upside from deal completion is likely limited, while downside reopens meaningfully only if regulators, financing, or litigation assumptions change.

From a broader healthcare lens, this favors acquirers with durable capital access and punishes subscale royalty platforms that need repeated dealmaking to manufacture growth. Expect peers to trade more on transaction scarcity than earnings quality over the next 1-2 months, with any follow-on M&A bid in the sector likely widening dispersion between cash-rich consolidators and asset accumulators.

Key Decisions for Investors

• Long LGND versus a basket of subscale royalty/asset aggregators for the next 4-8 weeks; the trade benefits if the market re-rates Ligand as the consolidator of choice while weaker peers are marked down on scarcity of attractive deal flow.
• Take profits on XOMA/XOMAP into deal completion rather than chasing the headline spread; the remaining upside is likely capped near the cash consideration, while breakup/regulatory downside is asymmetric if the close timeline slips.
• Buy LGND call spreads 1-3 months out to express upside from perceived M&A optionality and portfolio re-rating, with defined risk and limited theta bleed versus stock.
• Avoid long exposure to smaller royalty names that rely on serial acquisitions; the transaction implies that premium assets are being taken out rather than left for public market comp expansion.